SMSPHARMA SMS Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
SMS Pharma reported a strong FY26 with 13% revenue growth and 20% EBITDA margin, driven by strategic investments in backward integration and product diversification. While Q4 saw a slight margin dip due to raw material costs, the company is optimistic about future growth from ongoing capex, new product filings, and peptides development, guiding for 15% revenue growth and 20% EBITDA margin in FY27 amidst geopolitical uncertainties.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 4.0%, net profit up 65.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 197 | 173 | 248 | 196 | 242 +23% | 210 +21% | 238 −4% |
| EBITDA | 31 | 33 | 41 | 39 | 48 +55% | 44 +33% | 40 −2% |
| Net profit | 14 | 18 | 20 | 20 | 25 +79% | 23 +28% | 33 +65% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
